INCY Povofortay: First Oral Pill for HS, EU Nod

The EMA’s CHMP recommended approval of Incyte’s (INCY) Povofortay (povorcitinib) on September 17 for moderate-to-severe hidradenitis suppurativa (HS) in adults, positioning the once-daily pill to become the first oral treatment for the chronic skin disease. HS, also called acne inversa, causes painful lumps, abscesses, and tunnels under the skin, and it is often under-treated for years. Today’s approved treatments are all injectables: AbbVie’s Humira (adalimumab), Novartis’ Cosentyx (secukinumab), and UCB’s Bimzelx (bimekizumab).

Povorcitinib is a selective JAK1 inhibitor, the same enzyme class behind Incyte’s Jakafi for myelofibrosis and its topical Opzelura (ruxolitinib). Jakafi generates billions in annual revenue, so Incyte’s JAK chemistry is well characterized. By blocking the JAK1 signaling pathway, which relays inflammatory signals inside immune cells, the pill dampens the cascade that drives HS lesions. Its selectivity for JAK1 over JAK2 and JAK3 is meant to narrow the safety window relative to older, broader JAK inhibitors. Unlike IL-17 or TNF inhibitors, which block a single extracellular signal, JAK inhibitors act inside the cell, which is why regulators apply the boxed warning across the entire class.

In the two registrational STOP-HS trials, both the 45 mg and 75 mg once-daily doses met the primary endpoint: HiSCR50 response rates ran 40-42% versus 29-30% for placebo across STOP-HS1 and STOP-HS2, with a wider gap in patients who had previously been treated with a biologic. Longer-term data showed response rates climbing toward 70% by week 54. HS affects roughly 1% of the population, and most moderate-to-severe patients are treated with antibiotics or surgery rather than biologics. Many HS patients also discontinue injectable biologics because of injection-site pain or treatment fatigue, so a once-daily pill could reach patients the injectables never capture.

The asterisk is the class-wide boxed warning that JAK inhibitors carry for serious infections, death, malignancy, and major cardiovascular events. That matters in a chronic disease where patients stay on therapy for years, so real-world adoption will hinge on long-term safety, not just topline efficacy. Incyte has reported no new safety signals across the program, which is the argument it will lean on.

Incyte shares closed at $124.44 on September 24. The EU opinion de-risks the global filing, but the next binary event is the US, where the NDA was accepted in Q1 2026 and an FDA decision is expected in Q1 2027 under the PDUFA process. What to watch next is whether US regulators weigh the boxed warning the same way European ones did.

Source: European Medicines Agency, Povofortay (povorcitinib) CHMP opinion

What It Means for the Trade

The CHMP opinion is the de-risking event; the money event is the US decision in Q1 2027. Incyte is structurally a US-revenue story, and EU approval for a dermatology drug moves the stock only modestly — INCY closed at $124.44 — but it validates the STOP-HS dataset for the FDA and removes the scenario where European regulators balk at the class boxed warning first. Traders should treat the Q1 2027 PDUFA as the binary: an oral option in a market where every approved therapy is an injectable is a classic convenience-and-adherence play, and the longer-term data showing response rates climbing toward 70% by week 54 is the kind of durability curve that supports chronic use, which is where the revenue actually compounds.

The commercial logic is a segmentation trade. Humira, Cosentyx, and Bimzelx own the biologic-treatment segment; Povofortay’s realistic lane is patients who delay or refuse injections, cycle off biologics, or stall on antibiotics and surgical management — which the article notes is how most moderate-to-severe patients are treated today. That untreated pool is the upside. The known ceiling: JAK-class safety baggage will keep label positioning and payer coverage contested, and dermatologists burned by prior JAK controversies will start slow.

Mechanism and Pipeline Context

Povorcitinib selectively inhibits JAK1, one of four Janus kinases that relay cytokine signals inside immune cells. Blocking JAK1 dampens the inflammatory signaling that drives HS lesions at the intracellular source — mechanistically distinct from the biologics, which intercept a single extracellular cytokine like TNF-alpha or IL-17. For Incyte, this is a franchise extension of deep JAK chemistry: Jakafi (ruxolitinib) in myelofibrosis built the company, and topical Opzelura proved the JAK1 pathway works in skin. Povofortay is the systemic oral version aimed at inflammatory dermatology.

Pipeline-wise, the same molecule powers Incyte’s broader immunodermatology ambitions — HS is the lead indication, and povorcitinib has been studied in other inflammatory skin conditions (including vitiligo and prurigo nodularis programs), so an approval establishes the regulatory precedent for the whole platform. The JAK1 selectivity is the safety pitch: narrowing the enzyme target relative to older broad JAK inhibitors is meant to narrow the side-effect window, though the class-wide boxed warning for serious infections, death, malignancy, and major cardiovascular events still applies.

Risks and What Could Go Wrong

1. The FDA weighs the boxed warning harder than Europe did — HS is chronic and treated for years, so the US label could carry restrictive language that blunts adoption.
2. Safety signal with longer exposure — the climbing response curve is the bull case, but years-long JAK exposure in a non-life-threatening disease is precisely where real-world safety events surface.
3. Payer friction — a daily oral priced against entrenched biologics will face step-therapy edits that force biologic failure first, shrinking the reachable market.
4. Competition compresses the window — Bimzelx’s momentum in HS and the next wave of oral immunology assets could crowd the convenience lane before Povofortay’s US launch matures.